STOCK TITAN

Aravive Inc - ARAV STOCK NEWS

Welcome to our dedicated news page for Aravive (Ticker: ARAV), a resource for investors and traders seeking the latest updates and insights on Aravive.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aravive's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aravive's position in the market.

Rhea-AI Summary
Aravive, Inc. (Nasdaq: ARAV) has announced its intention to voluntarily terminate the listing of its common stock on the Nasdaq Global Select Market and deregister its common stock under the Securities Exchange Act of 1934. This decision follows the approval of effecting a transfer and assignment of all or substantially all of the Company’s assets to an assignee for the benefit of creditors and the dissolution and liquidation of the Company. The Company's non-compliance with the Minimum MVLS Requirement, Minimum MVPHS Requirement, and Minimum Bid Price Requirement has led to this decision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.45%
Tags
none
-
Rhea-AI Summary
Aravive's Phase 3 AXLerate-OC trial for batiraxcept in ovarian cancer did not meet primary endpoint of progression-free survival. Cash at end of Q2 is $18M, expected to fund operations into early Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-77.25%
Tags
-
Rhea-AI Summary
Aravive announces acceptance of two abstracts for poster presentation at ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.22%
Tags
conferences clinical trial
Rhea-AI Summary
Aravive, Inc. announced that its CEO, Gail McIntyre, will be participating in a fireside chat at the William Blair Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success on July 18, 2023. The event will be held virtually and a replay will be available for 7 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences
Rhea-AI Summary
Aravive, Inc. announces updated results from its Phase 2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 ASCO annual meeting. The results support the potential of batiraxcept plus cabozantinib combination therapy in ccRCC patients. A Phase 3 trial is planned to initiate in the second half of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.48%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
-
Rhea-AI Summary
Aravive reports Q1 2023 financial results and provides corporate updates, including progress in the development of batiraxcept in ovarian, kidney, and pancreatic cancer. The company remains on track for topline results from its platinum-resistant ovarian cancer (PROC) Phase 3 trial in mid-2023. Carolina Petrini has been appointed as Chief Commercial Officer. Updated data from the clear cell renal cell carcinoma (ccRCC) trial will be presented at ASCO 2023. Batiraxcept has been granted FDA Orphan Drug Designation in pancreatic cancer. Cash and cash equivalents as of March 31, 2023, were $35.9 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
conferences
Aravive Inc

Nasdaq:ARAV

ARAV Rankings

ARAV Stock Data

2.95M
45.08M
38.69%
8.21%
1.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Houston

About ARAV

versartis, inc. (nasdaq: vsar) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. the company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. versartis’ mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. learn more at www.versartis.com.